Quality of life assessment in cancer clinical research: current status and a look to the future

References

• American Cancer Society. Cancer Facts & Figures 2003 American Cancer Society, Atlanta, GA, USA (2003).
   Google Scholar
• O'Young J, McPeek B. Quality of life variables in surgical trials. j Chronic Dis. 40,513–522 (1987).
   PubMedGoogle Scholar
• Gotay CC, Wilson ME. Use of quality of life outcome assessments in current cancer clinical trials. Eva'. Health Prof 21,157–178 (1998).
   PubMed Web of Science ®Google Scholar
• Gotay CC, Phillips PH, Cheson BD. Male—female differences in the impact of cancer therapy. Oncology7, 67–74 (1993).
   Google Scholar
• Barr RD, Chalmers D, De Pauw S, Furlong W, Weitzman S, Feeny, D. Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: a cross-sectional study. j Clin. awl 18, 3280–3287 (2000).
   Google Scholar
• Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA etal Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. j Clin. 0=1 19, 1809-1817(2001).
   Google Scholar
• Bernhard J, Maibach R, Thurlimann B, Sessa C, Aapro MS. Patients' estimation of overall treatment burden: why not ask the obvious?' Clin. 0=1 20,65-72 (2002).
   Google Scholar
• Bonomi P, Kim KM, Fairclough D et al Comparison of survival and quality of life in advanced nonsmall-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Co-operative Oncology Group trial. Clin. 0=1 18,623-631 (2000).
   Google Scholar
• Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates and impact on quality of life. Clin. 0=1 18,743-753 (2000).
   Google Scholar
• Buzdar A, Douma J, Davidson N etal Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. j Clin. 0=1 19,3357-3366 (2001).
   Google Scholar
• Cheng JD, Hitt J, Koczwara B eta]. Impact of quality of life on patient expectations regarding Phase I clinical trial. Clin. Once]. 18,421–428 (2000).
   Google Scholar
• Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. j Clin. 0=1 19,72-80 (2001).
   Google Scholar
• Coates AS, Humy C, Peterson HF etal Quality-of-life scores predict outcome in metastatic but not early breast cancer. Clin. Once]. 18,3768–3774 (2000).
   Google Scholar
• Crivellari D, Bonetti M, Castiglione-Gertsch M et al Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. f Clin. 0=1 18,1412-1422 (2000).
   Google Scholar
• de Gramont A, Figer A, Seymour M eta]. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer" Clin. 0=1 18,2938-2947 (2000).
   Google Scholar
• de Wit R, Roberts JT, Wilkinson PM etal Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group and the Medical Research Council. f Clin. 19,1629–1640 (2001).
   Google Scholar
• Detmar SB, Aaronson NK, Weyer LDV, Muller M, Schomagel JH. How are you feeling? who wants to know? patients' and oncologists' preferences for discussing health-related quality-of-life issues. f Clin. 0=1 18,3295-3301(2000).
   Google Scholar
• •Includes data collected from patients receiving palliative chemotherapy and oncologists to illustrate how quality of life issues may be avoided in the oncologist's office. While patients wanted to talk about emotional functioning and daily activities with their physicians, they would only do so if the physician initiated the conversation. Physicians indicated that they deferred to patients when it came to initiating discussion of psychosocial issues.
   Google Scholar
• Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? evaluation of expectations, outcomes and costs in women receiving chemotherapy for advanced ovarian cancer. f Clin. 0=1 19, 1266–1274 (2001).
   Google Scholar
• Duvic M, Hymes K, Heald P etal Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational Phase II—III trial results. f Clin. 0=1 19, 2456–2471 (2001).
   Google Scholar
• Fossa SD, Slee PHT, Brausi M eta]. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J. Clin. awl 19, 62–71 (2001).
   Google Scholar
• •Illustrates how quality of life (Q00 data can affect the standard of cancer care. Patients with hormone resistant prostate cancer who were randomly assigned to receive prednisone reported better QOL and had equivalent time to progression and overall survival, compared with patients who received flutamide.
   Google Scholar
• Frasci G, Lorusso V, Panza N eta]. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall-cell lung cancer j Clin. awl 18, 2529–2536 (2000).
   Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhom LH. Clinical evaluation of once-weekly dosing of epoetin a in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.' Clin. Chrol 19, 2875–2882 (2001).
   Google Scholar
• Gattellari M, Voigt KJ, Butow PN, Tattersall MEIN. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J. Clin. 20, 503–513 (2002).
   Google Scholar
• Gatzemeier U, von Pawel J, Gottfried M et al Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced nonsmall-cell lung cancer. J. Clin. awl 18, 3390–3399 (2000).
   PubMed Web of Science ®Google Scholar
• Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J. Clin. amyl 18, 2395–2405 (2000).
   Google Scholar
• Hamilton AS, Stanford JL, Gilliland FD et al Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J. Clin. awl 19, 2517–2526 (2001).
   PubMed Web of Science ®Google Scholar
• Hobbie WL, Stuber M, Meeske K etal Symptoms of posttraumatic stress in young adult survivors of childhood cancer. J. Clin. awl 18, 4060–4066 (2000).
   PubMed Web of Science ®Google Scholar
• Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J. Clin. awl 18, 893–903 (2000).
   PubMed Web of Science ®Google Scholar
• Ingram SS, Seo PH, Martell RE etal Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J. Clin. awl 20, 770–775 (2002).
   PubMed Web of Science ®Google Scholar
• Jatoi A, Windschitl HE, Loprinzi CL al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J. Clin. 0=1 20, 567–573 (2002).
   Google Scholar
• Joly F, Heron JP, Kalusinski L et al Quality of life in long-term survivors of testicular cancer: a population-based case-control study 1 Clin. Oncol 20, 73–80 (2002).
   Google Scholar
• Jordhoy MS, Payers P, Loge JH, Ahlner- Elmqvist M, Kaasa S. Quality of life in palliative cancer care: results from a cluster randomized trial. J. Clin. 0=1 19, 3884–3894 (2001).
   Google Scholar
• Kaufmann M, Bajetta E, Dirix LY etal Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. Clin. 0=1 18, 1399–1411 (2000).
   Google Scholar
• Kelly K, Crowley J, Bunn PA Jr etal Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J. Clin. 0=1 19, 3210–3218 (2001).
   Google Scholar
• Kirkbride P Bezjak A, Pater J etal Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group Phase III Study. J. Clin. Oncol 18, 1960–1966 (2000).
   Google Scholar
• Klein M, Taphoom MB, Heimans JJ et al Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. j Clin. Oncol 19, 4037–4047(2001).
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Aaronson NK, de Jong JMA etal Prospective study on quality of life before and after radical radiotherapy in nonsmall-cell lung cancer j Clin. Oncol 19, 2123–2133 (2001).
   Google Scholar
• Lee SJ, Fairclough D, Parsons SK etal Recovery after stem-cell transplantation for hematologic diseases. J. Clin. Oncol 19, 242–252 (2001).
   PubMed Web of Science ®Google Scholar
• Leighl N, Gattellari M, Butow P, Brown R, Tattersall MEIN. Discussing adjuvant cancer therapy. J. Clin. amyl 19, 1768–1778 (2001).
   Google Scholar
• List MA, Stracks J, Colangelo L eta]. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment?j Clin. Oncol 18, 877 (2000).
   Google Scholar
• Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin a on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. amyl 19, 2865–2874 (2001).
   Google Scholar
• Macquart-Moulin G, Viens P, Palangie T etal High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment Clin. Oncol 18, 754–764 (2000)
   Google Scholar
• Madalinska JB, Essink-Bot M-L, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder PH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. Clin. amyl 19, 1619–1628 (2001).
   Google Scholar
• Maunsell E, Drolet M, Brisson J, Robert J, Deschenes L. Dietary change after breast cancer: extent, predictors and relation with psychological distress. J. Clin. amyl 20, 1017–1025 (2002).
   Google Scholar
• McLachlan SA, Allenby A, Matthews J etal Randomized trial of co-ordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. j Clin. Oncol 19, 4117–4125 (2001).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Hess KR, Yung WKA, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. j Clin. Oncol 18, 646–650 (2001).
   Google Scholar
• Middleton MR, Grob JJ, Aaronson N etal Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol 18, 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Lovato LC, Thompson IM Jr etal Profile of men randomized to the Prostate Cancer Prevention Trial: baseline health-related quality of life, urinary and sexual functioning and health behaviors. J. Clin. Oncol 18, 1942–1953 (2000).
   PubMed Web of Science ®Google Scholar
• Molenaar S, Sprangers MAG, Rutgers EJT et al Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction and quality of life. J. Clin. Ord 19, 1676–1687 (2001).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Murphy BA, Bacik J etal Phase III trial of interferon a-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J. Clin. Oncol 18, 2972–2980 (2000).
   Google Scholar
• Norris B, Pritchard KT, James K eta]. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. j Clin. Oncol 18, 2385–2394 (2000).
   Google Scholar
• Olsen E, Duvic M, Frankel A etal Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma j Gun. Oncol 19, 376–388 (2001).
   Google Scholar
• Ong LML, Visser MRM, Lammes FB, van der Velden J, Kuenen BC, de Haes JCJM. Effect of providing cancer patients with the audiotaped initial consultation on satisfaction, recall and quality of life: a randomized, double-blind study j Clin. Oncol 18, 3052–3060 (2000).
   Google Scholar
• Osoba D, Brada M, Yung WKA, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.j Gun. Oncol 18, 1481–1491 (2000) .
   Google Scholar
• Paltiel 0, Avitzour M, Peretz T etal Determinants of the use of complementary therapies by patients with cancer. j Gun. Oncol 19, 2439–2448 (2001).
   Google Scholar
• Piccart MJ, Green JA, Lacave AJ etal Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. Oncol 18, 1193–1202 (2000).
   Google Scholar
• Potosky AL, Knopf K, Clegg LX et al Quality-of-Life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study Oncol 19, 3750–3757 (2001).
   Google Scholar
• Quirt I, Robeson C, Lau CY etal Epoetin a therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. j Gun. Oncol 19, 4126–4134 (2001).
   Google Scholar
• Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-A Phase III trial of the Eastern Co-operative Oncology Group. j Gun. Oncol 19, 2114–2122 (2001).
   Google Scholar
• Segal R, Evans W, Johnson D, Smith D etal Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. Gun. Oncol 19,657–665 (2001).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R eta]. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. j Gun. Oncol 18, 2095–2103 (2000).
   Google Scholar
• Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flashstudies.j Gun. Oncol 19, 4280–4290 (2001).
   Google Scholar
• Small EJ, Meyer M, Marshall ME eta]. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. j Gun. Oncol 18, 1440–1450 (2000).
   Google Scholar
• Smith IE, O'Brien MER, Talbot DC et al Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. Oncol 19, 1336–1343 (2001).
   Google Scholar
• Socinski MA, Schell MJ, Peterman A etal Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIBAV non-small-cell lung cancer. j Gun. Oncol 20, 1335–1343 (2002).
   Google Scholar
• Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. j Gun. Oncol 18, 3912–3917 (2000).
   Google Scholar
• Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. j Gun. Oncol 18, 395–404 (2000).
   Google Scholar
• Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T Psychosocial characteristics of individuals with non-stage IVmelanomaj Gun. Oncol 19, 2844–2850 (2001).
   Google Scholar
• Velikova G, Wright P, Smith A. eta]. Self- reported quality of life of individual cancer patients: concordance of results with disease course and medical records. j Gun. Oncol 19, 2064-2073 (2001).
   Google Scholar
• Vokes EE, Kies MS, Haraf DJ etal Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. j Gun. Oncol 18, 1652–1661 (2000).
   Google Scholar
• Wei JT, Dunn RL, Sandler HM etal Comprehensive comparison of health-related quality of life after contemporary therapies for localized. j Gun. Oncol 20, 557–566 (2002).
   Google Scholar
• Spilker B (Ed.). Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott, PA, USA (1996). Encyclopedic text which is a key reference for reviews of specific quality of life (Q00 questionnaires, methodological issues in QOL research, and QOL findings in numerous diseases, including cancer.
   Google Scholar
• Gotay CC, Muraoka M. Quality of life in long-term survivors of cancer. j Natl Cancer Inst. 90, 656–667 (1998).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339 (1-15), 71–85 (1992) .
   Google Scholar
• Embretson SE, Reise SR Item Response Theory for fiychologists. Mahwah NJ (Ed.). Lawrence Erlbaum Associates, NJ, USA (2000).
   Google Scholar